Navigation Links
Preliminary Financial Results, Quarterly Reports and Upcoming Conference Schedules - Research Report on Avanir, BioScrip, Chemed, Foundation Medicine, and Antares
Date:11/11/2013

r basic and diluted share, compared with a net loss of $0.03 per basic and diluted share, in Q3 2012. "Last month's approval of OTREXUP represented a strategic milestone in the transformation of Antares from a royalty based business to a specialty pharmaceutical company generating potential product revenue from proprietary in-house development programs," said Paul K. Wotton, Ph.D., President and CEO of Antares. "We believe that OTREXUP could become an important part of the treatment continuum for RA patients and look forward to launching the product early in 2014." The Full Research Report on Antares Pharma, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:

[http://www.analystscorner.com/r/full_research_report/2353_ATRS]

----

EDITOR NOTES:

  1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.
  2. Information in this release is fact checked and produced on a best efforts basis and reviewed by Ananya Ghosh, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
  3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
  4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco@EquityNewsNetwork.com.
  5. For any urgent concerns or inquiries, please contact us at compliance@EquityNewsNetwork.com.
  6. Are you a public company? Would you like to see similar coverage on
    '/>"/>

SOURCE Analysts' Corner
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Preliminary Phase 2 Data of Ocera Therapeutics OCR-002 for the Treatment of Liver Cirrhosis and Upper GI Bleeding Show Potent Ammonia Reduction
2. OncoSec Presents Preliminary Safety Data for Phase II Melanoma Study at Second European Post-Chicago Melanoma Meeting 2012
3. Pro-Dex Provides Insight Into Fiscal 2013 Operating Plan And Preliminary Results For Fiscal 2012
4. Simcere Pharmaceutical Group Reports Preliminary Unaudited Second Quarter 2012 Results
5. Lexicon Pharmaceuticals Reports Preliminary Results From Two Phase 1 Studies
6. CareFusion To Report Preliminary Fiscal 2013 First Quarter Results On Nov. 8
7. Cardinal Health Announces Preliminary Shareholder Voting Results at 2012 Annual Meeting
8. CareFusion Reports Preliminary First Quarter Fiscal 2013 Results
9. OncoSec Medical Reports Positive Preliminary Efficacy Results from Phase II Study of ImmunoPulse in Metastatic Melanoma Patients
10. Simcere Pharmaceutical Group Reports Preliminary Unaudited Third Quarter 2012 Results
11. Avanir Pharmaceuticals Pre-Announces Preliminary Fiscal 2012 Fourth Quarter Results And Provides Clinical Study Update
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/22/2014)...   Zacks Equity Research highlights Epizyme (Nasdaq: EPZM ... Panera (Nasdaq: PNRA - Free Report ) as the Bear ... Amicus Therapeutics (Nasdaq: FOLD - Free Report ), Sanofi (NYSE: ... - Free Report ). Here is a synopsis of ... : The biotech bull market is far from ...
(Date:8/22/2014)... Aug. 22, 2014  Mark Riccio, director of ... facility, is using the online crowd-funding platform Kickstarter ... imaging to researchers and would-be superheros everywhere: "for ... would YOU do if you had Superman,s X-ray ... and explorers everywhere, from elementary through high school ...
(Date:8/22/2014)... , Aug. 22, 2014  Landauer, Inc. (NYSE: ... and environmental radiation measurement and monitoring, outsourced medical physics ... that William E. Saxelby , its President and ... and Chief Executive Officer and as a member of ... 2014.  He will be replaced on an interim basis ...
Breaking Medicine Technology:Epizyme, Panera, Amicus Therapeutics, Sanofi and Shire highlighted as Zacks Bull and Bear of the Day 2Epizyme, Panera, Amicus Therapeutics, Sanofi and Shire highlighted as Zacks Bull and Bear of the Day 3Epizyme, Panera, Amicus Therapeutics, Sanofi and Shire highlighted as Zacks Bull and Bear of the Day 4Epizyme, Panera, Amicus Therapeutics, Sanofi and Shire highlighted as Zacks Bull and Bear of the Day 5Epizyme, Panera, Amicus Therapeutics, Sanofi and Shire highlighted as Zacks Bull and Bear of the Day 6Cornell's X-ray Imaging Lab Director Uses Kickstarter Campaign to "Democratize" Advanced 3D Imaging 2Landauer, Inc. Announces Executive Management Change 2
... BEIJING, Nov. 11, 2010 /PRNewswire-Asia-FirstCall/ -- Dehaier Medical Systems ... "Company"), an emerging leader in the development, assembly, marketing ... in China, today announced that it will hold a ... quarter and nine months ended September 30, 2010. The ...
... KNDL ), a leading, global full-service clinical research ... Lazard Capital Markets 7th Annual Healthcare Conference on Nov. 16, ... City. Kendle,s formal presentation will be given at ... President and Chief Operating Officer and Keith Cheesman, Senior Vice ...
Cached Medicine Technology:Dehaier Medical Announces Conference Call to Discuss Third Quarter 2010 Financial Results 2Kendle to Present at Lazard Capital Markets 7th Annual Healthcare Conference 2
(Date:8/22/2014)... Counseling may do little to help young people with ... 66 studies that included nearly 18,000 people 25 and ... drinking problems. Participants in 49 studies attended a single ... the studies attended group sessions or a mix of ... motivational interviewing was used in the studies. This technique ...
(Date:8/22/2014)... FRIDAY, Aug. 22, 2014 (HealthDay News) -- College can be ... number of things they can do to make the most ... "a time to adjust, explore, meet new people and learn ... director of student wellness and assessment at St. John,s University ... "Not all learning takes place in the classroom. College ...
(Date:8/22/2014)... 22, 2014 Women with severe disabilities and multiple ... than women with no disabilities or no chronic conditions, ... screened less often than women with moderate disabilities or ... Sara Guilcher, an affiliate scientist with the Li Ka ... Guilcher said women with disabilities often have other measures ...
(Date:8/22/2014)... August 22, 2014 Ticket Down ... in Kalamazoo, New Orleans, Albuquerque and Rapid City. For ... “Long Island Medium,” Theresa Caputo, allows just that. Caputo was ... is part of a close knit family who began to ... a spiritual healer, realized she had a chance to do ...
(Date:8/22/2014)... (PRWEB) August 22, 2014 “Dr. Luciana Show ... Lagana , aka Dr. Luciana, is finding it challenging to ... and while taking care of hundreds of students, so the ... for the show is completed, and she recently entered it ... projects including those of her husband, actor/screenwriter Gregory Graham ...
Breaking Medicine News(10 mins):Health News:Counseling Does Little to Deter Youth Drinking, Review Finds 2Health News:College Prep 101 2Health News:Women with severe, chronic health issues are screened for breast cancer less often 2Health News:Theresa Caputo Tickets in Kalamazoo at Wings Stadium, Saenger Theatre in New Orleans, Kiva Auditorium in Albuquerque and Rapid City at Don Barnett Arena Now Available 2Health News:Professor Luciana Lagana Dedicates to Her CSUN Students the “Dr. Luciana Show-Aging and Falling” AOF Festival Nomination (Screening at Krikorian Monrovia Cinema on 08/25) 2Health News:Professor Luciana Lagana Dedicates to Her CSUN Students the “Dr. Luciana Show-Aging and Falling” AOF Festival Nomination (Screening at Krikorian Monrovia Cinema on 08/25) 3Health News:Professor Luciana Lagana Dedicates to Her CSUN Students the “Dr. Luciana Show-Aging and Falling” AOF Festival Nomination (Screening at Krikorian Monrovia Cinema on 08/25) 4
... among young inner-city children appears to be more unpredictable than ... a wise move as a hedge against dangerous flare-ups of ... study from the Johns Hopkins Childrens Center. Current asthma guidelines ... but six months may be too long for many patients, ...
... Johns Hopkins have evidence to explain why the supposedly natural ... factor for life-threatening heart failure. , In a ... Associations (AHA) annual Scientific Sessions in Orlando, Fla., the Hopkins ... and pumping function to assess minute changes in the hearts ...
... erase racial disparities, study suggests , SUNDAY, Nov. 4 (HealthDay ... patients vary widely by race and gender, a new U.S. ... South Carolina, Mt. Pleasant, noted that effective control of hypertension ... about actual rates of treatment and control. , The researchers ...
... from the Framingham Heart Study,link PAT signal with several cardio-vascular ... ... 4 Itamar Medical announced,confirmation of PAT technology by several ... Itamar Medical will now,promote clinical use in the medical community ...
... Carolina to increase the rate of coronary reperfusion (restoring ... significantly improved the quality of care these patients received, ... online to coincide with its release at the American ... in the November 28 print issue of JAMA. ...
... Combination Therapy Due to Flushing, ORLANDO, ... today,showed that Abbott,s SIMCOR(R), an investigational, fixed-dose ... met its primary endpoint of lowering plaque-promoting ... improvements,on other key lipids, LDL "bad" cholesterol, ...
Cached Medicine News:Health News:Urban kids with asthma need more frequent check-ups, Hopkins study suggests 2Health News:Aging heart changes shape, shrinks and loses pumping function too 2Health News:Aging heart changes shape, shrinks and loses pumping function too 3Health News:Poorer Blood Pressure Control in Blacks With Heart Failure 2Health News:New Research Released at AHA Confirms Itamar's PAT Technology to Diagnose Early Cardiovascular Disease 2Health News:Statewide program helps improve quality of care for heart attack 2Health News:Abbott's Investigational SIMCOR(R) Offers Comparable LDL Lowering to Simvastatin and Significantly Raises HDL and Lowers Triglycerides in Phase III Study 2Health News:Abbott's Investigational SIMCOR(R) Offers Comparable LDL Lowering to Simvastatin and Significantly Raises HDL and Lowers Triglycerides in Phase III Study 3Health News:Abbott's Investigational SIMCOR(R) Offers Comparable LDL Lowering to Simvastatin and Significantly Raises HDL and Lowers Triglycerides in Phase III Study 4Health News:Abbott's Investigational SIMCOR(R) Offers Comparable LDL Lowering to Simvastatin and Significantly Raises HDL and Lowers Triglycerides in Phase III Study 5
The DFS MiniFixator is a lightweight, external device for the treatment of small bone fractures and osteotomies....
The Elbow Fixator has ontrolled movement about the axis of rotation of the elbow joint. It is minimally invasive and rapidly applied....
... tradition of the original Hoffmann® Fixator, ... surgeon with advanced technology and ease ... snap fit mechanism allows the easy ... or pins providing versatile intraoperative frame ...
... safe and effective nonionic contrast medium well ... Worldwide, more than 250 million doses ... for a wide variety of radiological procedures, ... wide range of iodine concentrations and packaging ...
Medicine Products: